IP Library › Granted Patent US 12698347
Granted Patent B2
US 12698347 · App. 18/483,308 · Granted Aug 4, 2026

Bi-specific fusion proteins

Inventors: Ulrik Nielsen (Quincy, MA); Thomas Wickham (Groton, MA); Birgit Schoeberl (Cambridge, MA); Brian Harms (Roslindale, MA); Bryan Linggi (Richland, WA); Matthew Onsum (El Cerrito, CA); Byron DeLaBarre (Cambridge, MA); Shaun M. Lippow (San Francisco, CA)
Assignee: Silver Creek Pharmaceuticals, Inc.
C07K16/46A61K45/06A61K47/66A61K47/6811A61K47/6891B82Y5/00C07K14/47C07K14/475C07K14/485C07K14/65C07K16/44C12N15/62A61K38/00C07K2317/31C07K2317/76C07K2319/00C07K2319/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698347
App. No.
18/483,308
Granted
Aug 4, 2026
Kind
B2
Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Claims (20)

1 . A method for accumulating an IGF-1 fusion protein in cardiac tissue of a subject having myocardial infarction, the method comprising:

administering an effective amount of the IGF-1 fusion protein to the subject having myocardial infarction,

wherein the IGF-1 fusion protein comprises:

(i) a human IGF-1 having at least 98.5% identity with SEQ ID NO: 3;

(ii) a variant of human serum albumin having at least 95% identity with SEQ ID NO: 12, and comprising substitution of the cysteine residue corresponding to C34 to serine or alanine, and/or substitution of the asparagine residue corresponding to N503 to glutamine of SEQ ID NO: 12; and

(iii) optionally a connector polypeptide,

wherein the administering of the effective amount of the IGF-1 fusion protein to the subject results in accumulation of the IGF-1 fusion protein in the cardiac tissue, and

wherein the administering of the effective amount of the IGF-1 fusion protein to the subject results in reduction of the severity of the myocardial infarction.

2 . The method of claim 1 , wherein the IGF-1 is at the amino terminus of the fusion protein.

3 . The method of claim 1 , wherein the connector polypeptide is from 2 amino acids to 20 amino acids long.

4 . The method of claim 1 , wherein the connector polypeptide is a flexible or a structured polypeptide.

5 . A method for accumulating an IGF-1 fusion protein in cardiac tissue of a subject having myocardial infarction, the method comprising:

administering an effective amount of the IGF-1 fusion protein to the subject having myocardial infarction,

wherein the IGF-1 fusion protein comprises:

(i) a human IGF-1 having at least 98.5% identity with SEQ ID NO: 3;

(ii) a fragment of a human serum albumin comprising least at least 95% identity with Domain I comprising the amino acid sequence of SEQ ID NO: 27, Domain II comprising the amino acid sequence of SEQ ID NO: 25 or Domain III having the amino acid sequence of SEQ ID NO: 28; and

(iii) optionally a connector polypeptide,

wherein the administering of the effective amount of the IGF-1 fusion protein to the subject results in accumulation of the fusion protein in the cardiac tissue, and

wherein the administering of the effective amount of the IGF-1 fusion protein to the subject results in reduction of the severity of the myocardial infarction.

6 . The method of claim 5 wherein the fragment of human serum albumin comprises the amino acid sequence of SEQ ID NO: 24 or the amino acid sequence of SEQ ID NO: 26.